Home Merck Announces Settlement and License Agreement Resolving KEYTRUDA (pembrolizumab) Patent Litigation
 

Keywords :   


Merck Announces Settlement and License Agreement Resolving KEYTRUDA (pembrolizumab) Patent Litigation

2017-01-20 22:01:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada), and certain of its affiliates, today announced it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd., resolving the worldwide patent infringement litigation related to the use of an anti-PD-1 antibody for the treatment of cancer, such as KEYTRUDA (pembrolizumab). Language: English Contact: Merck Media: Pamela Eisele, 267-305-3558Claire Gillespie, 267-305-0932or Investors: Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more

Tags: agreement license patent settlement

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
22.11Spain fines budget airlines including Ryanair 179m
22.11Eastern North Pacific Tropical Weather Outlook
22.11Atlantic Tropical Weather Outlook
22.11Rush PANTS
22.11SBS
22.11/
22.11 YOU
22.11
More »